Leukotriene inhibitors in combination with steroids: potential role in the development of primary bacterial peritonitis.
Leukotrienes play a role in inflammation, and their participation in airway inflammation and bronchoconstriction in patients with severe asthma can be ameliorated by a new class of drugs known as leukotriene modulators. The role of leukotrienes in increasing vascular permeability in experimental peritonitis and in inducing chemotaxis of inflammatory cells has recently been documented. Steroids have been incriminated in the development of bacterial translocation in animal models in association with the suppression of mucosal immunity. The development of spontaneous bacterial peritonitis is recognized in cirrhotic patients with ascites and in those with nephrotic syndrome. The onset of bacterial peritonitis in the absence of these predisposing conditions or other underlying cause, such as perforated viscus, is termed 'primary bacterial peritonitis', and has never been described in asthmatic patients. We present an asthmatic patient who developed primary bacterial peritonitis while receiving a leukotriene modulator in combination with prednisolone therapy. The hypothesis that leukotriene receptor blockade might predispose to the development of primary bacterial peritonitis in patients receiving steroid therapy is discussed.
Farooq
Ansar
A
Manchester Royal Infirmary, Manchester, UK.
Ammori
Basil J
BJ
D000085:Acetates / Q000009:adverse effects*; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000139:chemically induced*; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D010533:Peritoneal Lavage; D010538:Peritonitis / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects*; D011804:Quinolines / Q000009:adverse effects*; D013440:Sulfides
D000085:Acetates; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D011239:Prednisolone; C093875:montelukast